- Conditions
- Idiopathic Solar Urticaria
- Interventions
- Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209), Ti02 pigmentary 3% alone (formula RV3131A-MV1211), bisoctrizole 10% alone (formula RV3131A-MV1237), Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213), Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329), Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212), Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)], V0096 CR vehicle (formula RV3131A-MV1197)
- Drug
- Lead sponsor
- Orfagen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–1
of 1
matching trial from the live ClinicalTrials.gov search.
Filters: Intervention: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213) Clear all